BioTech 365

DECEMBER 23, 2020

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO … Continue reading →

Gene Editing 40

Gene Editing Licensing Licensing Gene 40

BioTech 365

OCTOBER 19, 2021

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs … Continue reading →

Gene Editing 40

Gene Editing Engineer Licensing Licensing 40

pharmaphorum

JANUARY 10, 2024

Precision BioSciences licenses non-cancer uses of its allogeneic CAR-T therapy azer-cel to TG Therapeutics as it pivots to in vivo applications of its gene-editing technology

Gene Editing 111

Gene Editing In-Vivo Licensing Licensing 111

BioSpace

DECEMBER 12, 2023

The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.

Gene Editing 58

Gene Editing Licensing Licensing FDA Approval 58

pharmaphorum

OCTOBER 8, 2020

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. The big biotech meanwhile has an antisense drug in trials for a subtype of inherited ALS, licensed from Ionis Pharma, in phase 3 clinical trials. Jennifer Doudna.

Gene Editing 69

Gene Editing Gene In-Vivo Clinical Trials 69

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Drug Discovery Today

DECEMBER 2, 2020

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Licensing 45

Licensing Licensing Gene Editing Gene 45

BioTech 365

FEBRUARY 16, 2021

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models DUBLIN & BARCELONA, Spain–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide … Continue reading → (..)

Genome 52

Genome Genomics Licensing Licensing 52

Drug Discovery World

MAY 5, 2023

The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs). “We We are excited to bring this powerful platform into Eterna.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Gene Editing 52

Gene Editing Drugs Genome Genomics 52

Pharmaceutical Technology

APRIL 28, 2023

EDIT-301 is made of patient-derived CD34+ haematopoietic stem and progenitor cells, which are edited using CRISPR at the gamma globin gene (HBG1 and HBG2) promoter sites using a proprietary engineered AsCas12a nuclease, per the company’s website. Shoreline acquired EDIT-202 as part of this agreement.

Gene Therapy 264

Gene Therapy Drugs Gene Gene Editing 264

pharmaphorum

MAY 7, 2021

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

NOVEMBER 16, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT).

Gene Therapy 111

Gene Therapy Gene Gene Editing Clinical Trials 111

Drug Discovery World

JUNE 30, 2023

The European Patent Office (EPO) has granted a licensed patent to ONK Therapeutics covering CISH knockout (KO) in natural killer (NK) cells, irrespective of the source of the NK cells. ONK licensed the patent family relating to the KO of CISH in NK cells in an exclusive global patent license agreement from WEHI in 2021.

Gene Editing 52

Gene Editing Engineer Licensing Licensing 52

Drug Discovery World

MAY 9, 2024

The hTSC platform is the earliest ethically sourced pluripotent stem cells that are naive, powerful, lively and have high plasticity. hTSCs also naturally perform functions of many cell types and are immune privileged.

Engineer 64

Engineer Gene Editing Manufacturing Gene 64

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genome 52

Genome Genomics Reagent Gene Editing 52

pharmaphorum

JANUARY 10, 2022

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.

In-Vivo 52

In-Vivo Gene Editing Gene Therapy Gene 52

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Pharmaceutical Technology

MARCH 9, 2023

In 2022, Immatics and Editas Medicine entered a research collaboration and licensing agreement to combine gamma-delta T-cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. Bristol-Myers Squibb and Cellectis are the other key patent filers in in-vitro T-cell activation.

In-Vitro 130

In-Vitro Gene Editing Medicine Licensing 130

Drug Discovery World

FEBRUARY 16, 2023

Aera’s technology also includes a licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene editing enzymes. The post Start-up aims to advance transformative genetic medicines appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Gene Editing In-Vivo 52

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

Pharmaceutical Technology

JANUARY 19, 2023

Despite the challenges faced by gene-modified cell therapies such as CAR-T cells, significant promise remains for allogeneic cell therapies that have not been gene edited. NiCord’s biologics license application is currently being investigated by the FDA with a review date set by May 2023.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

APRIL 25, 2023

After missing the previous Q1 deadline, bluebird bio has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its sickle cell disease gene therapy lovo-cel, based on an April 24 company announcement.

Gene Therapy 130

Gene Therapy Gene Gene Editing Licensing 130

Drug Discovery World

MAY 6, 2024

The transfer of technologies from the lab to the market, is no longer purely via IP out licensing, but rather via start-up M&A deals – start-ups being the de-risking vehicle for large corporates. One such company, drawing on Vilnius’ gene editing expertise, is Caszyme, which was founded by Professor Šikšnys.

Drugs 59

Drugs Life Science Gene Editing Gene 59

The Pharma Data

AUGUST 4, 2020

UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector platform, for tis application in next-generation CAR-T programmes in oncology. .

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42

pharmaphorum

DECEMBER 21, 2022

As part of the acquisition, Kite will assume responsibility for continuing the R&D collaboration between Tmunity and Penn, which includes options and licenses to cell engineering and manufacturing technologies invented and developed in the university’s laboratories. Image by Anja from Pixabay .

Gene Editing 52

Gene Editing Licensing Licensing Manufacturing 52

pharmaphorum

SEPTEMBER 29, 2020

For example, under a traditional pharma/biotech collaboration and licensing model, a biotech partner may have primary responsibility for significant elements of research and early product development, and the pharma partner may lead the majority of later stage development, as well as post-approval commercial manufacture and supply.

Research 132

Research Gene Editing Gene Development 132

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

XTalks

MAY 22, 2023

Related: 5 Food Companies Working With Precision Fermentation Technology How Pairwise Leverages CRISPR Technology CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technique that can be used to alter the DNA of cells to enhance certain characteristics or reduce less desirable ones.

Branding 98

Branding Gene Editing DNA Production 98

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. In an interview with BioSpace, De Backer outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space. Photo courtesy of Bayer.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

Drug Discovery World

JULY 10, 2023

Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing. As a result, model generation is an attractive option often considered in parallel. However, the creation of custom mouse models remains a complex process that comes with significant risk(s). (B)

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

pharmaphorum

JUNE 17, 2022

Other programmes for the disease that have fallen by the wayside in recent years include C9ORF72-targeitng antisense drug BIIB078 , which failed a trial reported in March, and type 2B activin receptor antagonist BIIB110, licensed from AliveGen. The post Biogen waves bye to $217m ALS partnership with Karyopharm appeared first on.

Gene Editing 40

Gene Editing Trials Licensing Licensing 40

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. CRISPR and brain cancer Meanwhile, elsewhere in the US, another exciting development – using CRISPR as a therapeutic approach – has possibilities for tackling brain cancer.

Development 64

Development Research Drugs Antibody 64

Delveinsight

MARCH 2, 2021

In return, HitGen will receive an upfront payment, success fee, license/milestone fee from UPPTHERA, details of which remain undisclosed. HitGen plans to apply its platform technology based on the design, synthesis, and screening of DNA-encoded libraries (DEL) for the discovery of compounds to bind to specific targets.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The

Genome 52

Genome Genomics Licensing Licensing 52